AMAG Pharma (AMAG) Posts Q4 EPS of $0.10 on Tax Reform Gain

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/1/2026

1. INTC
2. AMZN
3. RDDT
4. COIN
5. PINS
6. FSLR
7. SYK
8. DASH
9. GILD
10. SBUX

Go back to AMAG Pharma (AMAG) Posts Q4 EPS of $0.10 on Tax Reform Gain

AMAG Reports 2017 Financial Results and Company Update

February 27, 2018 7:00 AM EST

2017 GAAP Revenue Increased 15% Year-over-Year

February 2018: Company Secures Two U.S. Food and Drug Administration (FDA) Approvals

Conference Call Scheduled for 8:00 a.m. ET Today

WALTHAM, Mass., Feb. 27, 2018 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today reported unaudited consolidated financial results for the fourth quarter and full year ended December 31, 2017.

Total GAAP revenue for the full year of 2017 increased approximately 15% to $609.9 million, driven by increased sales growth across AMAG's portfolio, which includes Makena® (hydroxyprogesterone caproate injection), Feraheme® (ferumoxytol... More